MedImmune LLC:企業の戦略的SWOT分析

◆英語タイトル:MedImmune LLC - Strategic SWOT Analysis Review
◆商品コード:DATA904C15788
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

MedImmune LLC – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture, and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting various diseases. MedImmune undertakes research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases. It also develops vaccines for the prevention of infectious diseases. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US.

MedImmune LLC Key Recent Developments

Feb 14,2019 “MedImmune” brand to be retired as biologics integrate into AstraZeneca’s new R&D structure
Dec 04,2018 CELLINK announces collaboration with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discovery
Sep 14,2018 US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia[Newswire : Healthcare-BW]
Aug 20,2018 AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018
Jun 18,2018 N4 Pharma: Update on Nuvec

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
MedImmune LLC – Key Facts
MedImmune LLC – Key Employees
MedImmune LLC – Key Employee Biographies
MedImmune LLC – Major Products and Services
MedImmune LLC – History
MedImmune LLC – Company Statement
MedImmune LLC – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
MedImmune LLC – Business Description
MedImmune LLC – SWOT Analysis
SWOT Analysis – Overview
MedImmune LLC – Strengths
MedImmune LLC – Weaknesses
MedImmune LLC – Opportunities
MedImmune LLC – Threats
MedImmune LLC – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
MedImmune LLC, Recent Deals Summary
Section 4 – Company’s Recent Developments
Feb 14, 2019: “MedImmune” brand to be retired as biologics integrate into AstraZeneca’s new R&D structure
Dec 04, 2018: CELLINK announces collaboration with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discovery
Sep 14, 2018: US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia[Newswire : Healthcare-BW]
Aug 20, 2018: AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018
Jun 18, 2018: N4 Pharma: Update on Nuvec
Apr 04, 2018: AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC
Feb 28, 2018: MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
Jan 01, 2018: New Bio-Incubator and Life-Science Accelerator Capability Launches at the Babraham Research Campus
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
MedImmune LLC, Key Facts
MedImmune LLC, Key Employees
MedImmune LLC, Key Employee Biographies
MedImmune LLC, Major Products and Services
MedImmune LLC, History
MedImmune LLC, Other Locations
MedImmune LLC, Subsidiaries
MedImmune LLC, Key Competitors
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
MedImmune LLC, Recent Deals Summary

List of Figures
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MedImmune LLC, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[MedImmune LLC:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Catasys Inc (CATS):企業財務及び戦略的SWOT分析
    Summary Catasys Inc (Catasys) is a healthcare service provider that leads the health care industry in improving health and reducing claims costs for health plan members with behavioral health (BH) disorders. The company offers OnTrak, a fifty two week intensive outpatient program, treats an overlook …
  • The Alumasc Group plc (ALU):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "The Alumasc Group plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly fol …
  • Saxo Bank A/S:企業のM&A・事業提携・投資動向
    Saxo Bank A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Saxo Bank A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Pla Matels Corporation (2714):企業概要、財務及び戦略的SWOT分析
    Summary Pla Matels Corporation (Pla Matels) is a synthetic resin manufacturing company. The company produces, sells and purchases various types of plastic resins and plastic products, plastic sheets, plastic filters, machines for injection/extrusion and related equipment. Its products include raw pl …
  • Resonance Health Ltd (RHT):企業の財務・戦略的SWOT分析
    Summary Resonance Health Ltd (Resonance Health) is a healthcare solution provider that offers non-invasive medical imaging software and services. The company offers FerriScan analysis software for the measurement of liver iron concentration (LIC); FerriScan with Cardiac T2* dual analysis service to …
  • Green Cross Cell Corp (031390):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross Cell Corp (Green Cross Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of co …
  • Evgen Pharma Plc (EVG):企業の財務・戦略的SWOT分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company focused on the development of sulforaphane-based compounds for the treatment of cancer and neurological disease. Its pipeline product SFX-01 targets STAT3 signalling to inhibit stem-like c …
  • Keller Group Plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Keller Group Plc Mergers and Ac …
  • Acea S.p.A:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Acea S.p.A Mergers and Acquisit …
  • VTB Bank:戦略・SWOT・企業財務分析
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • MetLife, Inc.:企業の戦略・SWOT・財務情報
    MetLife, Inc. - Strategy, SWOT and Corporate Finance Report Summary MetLife, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Neograft Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Neograft Technologies Inc (Neograft) is a medical device company that cardiac technologies for use in heart bypass procedures. The company offers solutions such as saphenous vein harvesting, coronary artery bypass graft, and others. It develops and provides angioshield, which is a transforma …
  • Sundaram Multi Pap Ltd.の企業概要及び財務/SWOT分析
    Sundaram Multi Pap Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarter …
  • RungePincockMinarco Limited (RUL):企業の財務及び戦略的SWOT分析
    Summary RungePincockMinarco Limited (RungePincockMinarco) is a mining advisory and consulting service company that develops mining software solutions, advisory services and professional development. The company offers mining software for mine planning, scheduling, equipment simulation and financial …
  • AVEO Pharmaceuticals Inc (AVEO):製薬・医療:M&Aディール及び事業提携情報
    Summary AVEO Pharmaceuticals Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candida …
  • Australian Solomons Gold Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Australian Solomons Gold Limite …
  • Salient Surgical Technologies, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Salient Surgical Technologies, …
  • AltheaDx, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' AltheaDx, Inc. Mergers and Acqu …
  • Kirby Corporation:企業の戦略・SWOT・財務情報
    Kirby Corporation - Strategy, SWOT and Corporate Finance Report Summary Kirby Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Clayton Homes Inc:企業の戦略・SWOT・財務情報
    Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report Summary Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆